Drug Trial Radar · NCT05822908
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Feb 14, 2023
Primary completion
Apr 1, 2028
Study completion Oct 15, 2028
Sponsor
- Lead sponsor
- Vico Therapeutics B. V.Industry
- Sponsor type
- Industry
- First posted
- Apr 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.
Conditions
- Spinocerebellar Ataxia Type 1
- Spinocerebellar Ataxia Type 3
- Huntington Disease
Interventions
VO659Drug
VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence & dose relationships of treatment-related AEs, SAEs, AEs of special interest (AESI), severe events (NCI- CTCAE Grade 3 or higher).Time frame: Day 0-253
- Vital signsTime frame: Day 0-253
- Body weightTime frame: Day 0-253
- Electrocardiogram (ECG) RR intervalTime frame: Day 0-253
- Electrocardiogram (ECG) - PR intervalTime frame: Day 0-253
- Electrocardiogram (ECG) - QTc intervalTime frame: Day 0-253
- Laboratory safety parameters in blood - white blood cell countTime frame: Day 0-253
- Laboratory safety parameters in blood - hemoglobinTime frame: Day 0-253
- Laboratory safety parameters in blood - plateletsTime frame: Day 0-253
- Laboratory safety parameters in blood - prothrombin time (PT)Time frame: Day 0-253
- Laboratory safety parameters in blood - activated partial thromboplastin clotting time (aPTT)Time frame: Day 0-253
- Laboratory safety parameters in blood - international normalised ratio (INR)Time frame: Day 0-253
- Laboratory safety parameters in blood - blood urea nitrogenTime frame: Day 0-253
- Laboratory safety parameters in blood - carbon dioxideTime frame: Day 0-253
- Laboratory safety parameters in blood - creatinineTime frame: Day 0-253
- Laboratory safety parameters in blood - glucoseTime frame: Day 0-253
- Laboratory safety parameters in blood - chlorideTime frame: Day 0-253
- Laboratory safety parameters in blood - potassiumTime frame: Day 0-253
- Laboratory safety parameters in blood - sodiumTime frame: Day 0-253
- white blood cell (WBC) count in cerebrospinal fluid (CSF)Time frame: Day 0-253
- Protein levels in cerebrospinal fluid (CSF)Time frame: Day 0-253
- Structural imaging assessment of any new abnormalitiesTime frame: Day 0-253
- Percentage of participants with suicidal ideation or behaviour, as assessed by the Columbia suicide severity rating scale (C-SSRS).Time frame: Day 0-253
Locations
14 sites in 6 countries. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark · Recruiting
Centre Hospitalier Universitaire dÁngers
Angers, France · Recruiting
CHU Gui de Chauliac Montpellier- Expert Center of Neurogenetic diseases, Department of Neurology
Montpellier, France · Recruiting
Universtiry Hospitals Pitie Salpetriere - Charles foix - Paris
Paris, France · Recruiting
Katholisches Klinikum Bochum
Bochum, Germany · Recruiting
Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE)
Bonn, Germany · Recruiting
Universitatsklinikum Essen - Neurologie
Essen, Germany · Recruiting
Universitatsklinikum Tübingen
Tübingen, Germany · Recruiting
Meir Medical Center
Kfar Saba, Israel · Recruiting
Sourmansky Medical Center
Tel Aviv, Israel · Recruiting
Leiden University Medical Center LUMC
Leiden, Netherlands · Active not recruiting
Radbout University Medical Centre
Nijmegen, Netherlands · Active not recruiting
University College London Hospitals NHS Foundation
London, United Kingdom · Recruiting
John Radcliffe Hospital
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.